Moderna Inc. (MRNA)
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
Analysts come up with their key catalyst watch list that can help Moderna shares get out of the rut.
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
Moderna may have a number of new product launches ahead. Pfizer is a big pharma stock that's poised for a big comeback.
Investors who Lost Money on Moderna, Inc. (MRNA) Should Contact Levi & Korsinsky About Pending Class Action - MRNA
NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Moderna, Inc. to Contact the Firm Today!
NEW YORK CITY, NY / ACCESSWIRE / September 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
S&P 500 Gains and Losses Today: Moderna Stock Plunges as Firm Plans R&D Cuts
Major U.S. equities indexes headed higher after the latest Producer Price Index (PPI) report showed a cooldown in wholesale inflation in August, the latest data point that could tip the scales toward an interest-rate cut when the Federal Reserve meets next week.
Class Action Filed Against Moderna, Inc. (MRNA) - October 8, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Stock Plummets on Cost-Cutting Measures
Shares of Moderna Inc (NASDAQ:MRNA) are plummeting today, after the biotech giant announced it was slashing its research budget by about 20%.
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.
The Schall Law Firm Seeks Investor Participation In A Securities Fraud Case Against Moderna, Inc.
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Shareholders That Lost Money on Moderna, Inc. (MRNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna shares tank after announcing $1.1bn cost-cutting measures
US pharmaceuticals giant Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares tanked more than 17% on Thursday after announcing a $1.2 billion cost-cutting plan in its research and development department. Moderna successfully commercialised its Covid-19 vaccine at the height of the pandemic leading to an all-time high valuation in September 2021.
